Results 31 to 40 of about 4,368 (201)

Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy [PDF]

, 2021
Introduction: FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) investigated the nonsteroidal, selective mineralocorticoid receptor (MR) antagonist finerenone in patients with CKD and type 2 diabetes ...
Kooy, Adriaan, McCafferty, Kieran, Et al., Filippatos, Gerasimos S., Ruilope Urioste, Luis Miguel, Chan, Juliana C. N., Rossing, Peter, Agarwal, Rajiv L., FIDELIO-DKD, Pitt, Bertram, Anker, Stefan D., Wanner, Christoph, Anker, Stefan D, Chan, Juliana C N, Filippatos, Gerasimos, Scott, Charlie, Chan, Juliana C.N., Agarwal, Rajiv, Schernthaner, Guntram, Joseph, Amer, Bakris, George L., Ruilope, Luis M., Scheerer, Markus F, Bakris, George L, FIDELIO-DKD Investigators, Scheerer, Markus F., Ruilope, Luis M, Christoph Wanner, Gerasimos Filippatos, Amer Joseph, Markus F. Scheerer, Charlie Scott, Stefan D. Anker, Juliana C.N. Chan, Adriaan Kooy, Rajiv Agarwal, Peter Rossing, Luis M. Ruilope, Bertram Pitt, George L. Bakris, Guntram Schernthaner, Kieran McCafferty   +41 more
core   +2 more sources

Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus

Diabetology & Metabolic Syndrome, 2023
Background Finerenone is a third-generation mineralocorticoid receptor antagonists, which has shown good cardiac function improvement in patients with type 2 diabetes in large-scale clinical trials.
Tao Jin, Xiangrui Fu, Ming Liu, Fengshuang An   +3 more
doaj   +1 more source

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease

, 2023
Nonsteroidal mineralocorticoid receptor antagonists (MRAs) present a promising therapeutic option in cardiorenal diseases, mitigating the limitations of steroidal MRAs.
Monarch Shah, Alaa Awad, Emaad Abdel-Rahman   +2 more
core   +1 more source

Finerenon: farmakologický profil

Klinická farmakologie a farmacie, 2023
Finerenon je nesteroidní antagonista mineralokortikoidního receptoru. Kromě vysoce selektivní blokády nadměrné aktivace tohotoreceptoru u kardiorenálních onemocnění také inhibuje aktivaci specifických kofaktorů zapojených v expresi genů zapojenýchv patofyziologii zánětu, fibrotizace a hypertrofie tkání.
openaire   +2 more sources

Association of finerenone with prognosis and safety in diabetic kidney disease patients: an undated meta-analysis based on four RCTs

Frontiers in Medicine
BackgroundAlthough current guidelines have recommended finerenone as a first-line agent for patients with diabetic kidney disease (DKD), it is unclear what effect finerenone has on all-cause and cardiovascular mortality.
Zixuan Zhang, Fan Zhang, Yan Bai, Jiao Li, Yifei Zhong   +4 more
doaj   +1 more source

Characteristics of patients with chronic kidney disease and Type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study

Journal of Comparative Effectiveness Research, 2023
Aim: Finerenone is safe and efficacious for treating patients with chronic kidney disease (CKD) and Type 2 diabetes (T2D). Evidence on the use of finerenone in clinical practice is lacking.
David Vizcaya, Csaba P Kovesdy, Andres Reyes, Elena Pessina, Pau Pujol, Glen James, Nikolaus G Oberprieler   +6 more
doaj   +1 more source

Finerenone improves vascular function in association with reduced aortic sodium content in aldosterone/salt-loaded uninephrectomized rats

Journal of Pharmacological Sciences
Mineralocorticoid receptor (MR) overactivation and high salt intake drive vascular dysfunction, characterized by endothelial impairment and stiffening.
Md. Moshiur Rahman, Asadur Rahman, Masashi Tawa, Hiroyuki Ohsaki, Keisuke Nakagawa, Netish Kumar Kundo, Akram Hossain, Juanjuan Ye, Liu Changjin, Md. Enayet Kabir, Daisuke Yamazaki, Takashi Morikawa, Yoshio Konishi, Mamoru Ohkita, Kento Kitada, Akira Nishiyama   +15 more
doaj   +1 more source

Finerenone for the treatment of patients with chronic kidney disease

, 2022
Finerenone for the treatment of patients with chronic kidney ...
Provenzano M., Gesualdo L., De Nicola L., La Manna G.   +3 more
core  

Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonist finerenone in the management of diabetic kidney disease: A meta-analysis

Indian Journal of Endocrinology and Metabolism, 2022
Background: Data are scant on use of finerenone in diabetic kidney disease (DKD). We undertook this meta-analysis to address this knowledge gap. Methods: Electronic databases were searched for randomized controlled trials (RCTs) involving diabetes ...
Deep Dutta, Vineet Surana, Saptarshi Bhattacharya, Sameer Aggarwal, Meha Sharma   +4 more
doaj   +1 more source

Finerenone in IgA nephropathy: real-world 12-month propensity-matched cohort demonstrating proteinuria reduction, eGFR preservation, and safety profile

Renal Failure
Objective To evaluate the efficacy and safety of finerenone in patients with IgA nephropathy (IgAN).Methods This retrospective study included 105 patients with IgAN (35 in the finerenone group, 70 in the control group) from January 2022 to February 2025.
Wei Zhang, Jing-ting Yu, Bo Lin, Xiaogang Shen, Maosheng Chen, Yi-dong Zhou, Yu-jia Zhang, Cheng-cong Zhuo, Zhi-liang Jiang, Bin Zhu   +9 more
doaj   +1 more source